CalciMedica (NASDAQ:CALC) Announces Quarterly Earnings Results

CalciMedica (NASDAQ:CALC) released its quarterly earnings data on Wednesday. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.41) by ($0.11), FiscalAI reports.

CalciMedica Stock Up 3.2%

Shares of CalciMedica stock traded up $0.10 on Wednesday, hitting $3.31. 24,816 shares of the company’s stock traded hands, compared to its average volume of 48,777. The company has a quick ratio of 5.45, a current ratio of 5.45 and a debt-to-equity ratio of 1.39. CalciMedica has a 52-week low of $1.42 and a 52-week high of $4.26. The firm’s 50-day moving average is $3.14 and its 200 day moving average is $2.55. The stock has a market cap of $47.72 million, a P/E ratio of -2.06 and a beta of 1.37.

Insider Activity

In related news, insider Eric W. Roberts bought 9,200 shares of the firm’s stock in a transaction on Thursday, August 28th. The stock was bought at an average cost of $2.86 per share, for a total transaction of $26,312.00. Following the completion of the purchase, the insider directly owned 70,107 shares in the company, valued at approximately $200,506.02. The trade was a 15.10% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Sudarshan Hebbar bought 9,563 shares of the stock in a transaction dated Tuesday, August 19th. The shares were bought at an average cost of $2.82 per share, with a total value of $26,967.66. Following the completion of the acquisition, the insider directly owned 61,539 shares of the company’s stock, valued at approximately $173,539.98. The trade was a 18.40% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last quarter, insiders have purchased 50,366 shares of company stock worth $144,317. 41.55% of the stock is owned by company insiders.

Institutional Investors Weigh In On CalciMedica

An institutional investor recently raised its position in CalciMedica stock. Cetera Investment Advisers lifted its position in shares of CalciMedica Inc. (NASDAQ:CALC) by 33.1% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 36,385 shares of the company’s stock after acquiring an additional 9,045 shares during the period. Cetera Investment Advisers owned 0.26% of CalciMedica worth $58,000 as of its most recent filing with the SEC.

Analyst Ratings Changes

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of CalciMedica in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $16.00.

About CalciMedica

CalciMedica, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia.